



Company Overview

Natus delivers innovative and trusted solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems to advance the standard of care and improve patient outcomes and quality of life. The Company offers hardware, advanced software and algorithms, and consumables that provide stimulus, acquire and monitor physiological signals, and capture the body's response. With sales in over 100 countries, Natus is a leader in neurodiagnostics, pediatric retinal imaging, and infant hearing screening, as well as a leading company in hearing assessment, hearing instrument fitting, balance, and intracranial pressure monitoring.

ArchiMed completes acquisition of Natus Medical Incorporated for \$1.2 billion total equity value

Jul 21 2022, 9:13 AM EDT

Natus Medical Announces First Quarter 2022 Financial Results

May 5 2022, 4:01 PM EDT

Natus Medical Incorporated to be acquired by ArchiMed Group for \$33.50 per share in cash

Apr 18 2022, 7:00 AM EDT

Investor Relations

Natus Medical Incorporated
Drew Davies
Chief Financial Officer
T: (925) 223-6700
InvestorRelations@Natus.com

Management Team

Thomas J. Sullivan

Chief Executive Officer

Drew Davies

Executive Vice President and Chief Financial Officer

Austin F. Noll, III

President

Monther Abushaban

Vice President, Quality Assurance

Douglas Balog

Vice President and General Counsel

Seán Langan

Vice President Global Operations

Lisa Paul

Vice President and Chief People Officer

Nitin Shali

Vice President, Research and Development

Natus Medical Incorporated

3150 Pleasant View Road
Middleton, WI 53562

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.